A Phase 1b/2, Multi-center, Uncontrolled, Open-label, Dose Escalation Study of Refametinib (BAY86-9766) in Combination With Regorafenib (BAY73-4506) in Patients With Advanced or Metastatic Cancer
Phase of Trial: Phase I/II
Latest Information Update: 30 Jan 2018
Price : $35 *
At a glance
- Drugs Refametinib (Primary) ; Regorafenib (Primary)
- Indications Breast cancer; Colorectal cancer; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Bayer
- 30 Nov 2016 Status changed from completed to discontinued.
- 25 May 2016 Status changed from active, no longer recruiting to completed.
- 22 Apr 2016 Planned End Date changed from 1 Mar 2016 to 1 Apr 2016.